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ABSTRACT
Background: Vitamin D insufficiency is common in older people
and may lead to increased bone resorption, bone loss, and increased
falls and fractures. However, clinical trials assessing the effect of
vitamin D supplementation on bone mineral density (BMD) have
yielded conflicting results.
Objectives: This study examined the effect of vitamin D supplemen-
tation on BMD at the hip, using dual-energy X-ray absorptiometry.
Methods:A total of 379 adults aged≥70 y (48% women; mean age:
75 y) from the northeast of England were randomly allocated to 1
of 3 doses of vitamin D3 [12,000 international units (IU), 24,000
IU, or 48,000 IU] given once a month. The primary outcome was
change in BMD (BMD) at the hip. Secondary endpoints comprised
the dose effects on femoral neck BMD, falls, circulating calciotropic
hormones, bone turnover markers, and adverse events.
Results: The mean ± SD baseline plasma 25-hydroxyvitamin D
[25(OH)D] concentration was 40.0 ± 20.1 nmol/L, which increased
after 12 mo to a mean 25(OH)D of 55.9, 64.6, or 79.0 nmol/L
for participants receiving a monthly dose of 12,000, 24,000, or
48,000 IU, respectively (P < 0.01 for difference). There was no
between-group difference inBMD.However, parathyroid hormone
concentrations decreased in all 3 groups, with a significantly greater
decrease in the 48,000-IU group compared with the 12,000-IU group
(P< 0.01). There were no differences in any adverse events between
groups, with 3 cases of hypercalcemia, none of nephrolithiasis, and
249 falls observed.
Conclusions: There was no difference in change in BMD over
12 mo between the 3 doses of vitamin D, suggesting no effect of
the intervention or a similar attenuation of the anticipated decrease
in BMD over 12 mo. The treatment was safe and effective in
increasing plasma 25(OH)D concentrations, with no dose-related
adverse events. This trial was registered at the EU Clinical Trials
Register (EudraCT 2011-004890-10) and the ISRCTN Registry
(ISRCTN35648481). Am J Clin Nutr 2019;109:207–217.
Keywords: vitamin D, older people, randomized controlled trial,
bone mineral density, dual-energy X-ray absorptiometry
Introduction
Vitamin D insufficiency is common in older people and may
lead to increased bone resorption, bone loss, impairment of
muscle function, and an increased risk of falls and fractures.
The results of clinical trials assessing the effect of vitamin D
supplementation on bone mineral density (BMD), bone loss,
falls, and fractures have yielded conflicting results, and, although
a recent meta-analysis of clinical trials reported a possible
relation between vitamin D supplementation and higher BMD at
the neck of femur, it suggested that supplementation with vitamin
D has a benefit for bone health only in those at risk of vitamin D
deficiency (1).
Internationally, guidelines differ in their recommendations for
vitamin D status for musculoskeletal health, as reflected by
circulating 25-hydroxyvitamin D [25(OH)D] concentrations: in
the United Kingdom, the Scientific Advisory Committee on Nu-
trition (SACN) recommends a concentration of ≥25 nmol/L (2).
In North America, the Institute of Medicine (IOM) recommends
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a concentration of 50 nmol/L (3), whereas the Endocrine Society
clinical guideline recommends a target concentration of 75
nmol/L for the maintenance of bone health and other nonskeletal
benefit (4). The UK dietary Reference Nutrient Intake is 10 μg
[400 international units (IU)]/d (2), whereas in North America,
the Recommended Dietary Allowance (RDA) for those aged>70
y is 20 μg (800 IU)/d (3). However, in this age group in the
United Kingdom, the mean daily vitamin D intake from dietary
sources (including nutritional supplements) is ∼5.2 μg (208
IU)/d (2), and medical prescription of vitamin D supplements
is relatively uncommon, even among those at highest risk
(5, 6).
Decreased dose frequency has been identified as a factor
associated with better adherence to pharmacological therapy (7),
and because plasma 25(OH)D has a half-life estimated in terms of
weeks rather than hours (8–10), daily dosing may not be required
to maintain an adequate vitamin D status. However, decreasing
dose frequency may have unanticipated effects. For example,
one clinical trial evaluating an annual oral dose of 12,500 μg
(500,000 IU) vitamin D found that there was an increase in falls
and fractures (11).
Overall, previous study findings are conflicting, which may
reflect variations in study design, the characteristics of partici-
pants (such as age, frailty, and baseline vitamin D status), and the
nature of intervention, including vitamin D dose, its route, the
frequency of administration, and the form of vitamin D (whether
vitamin D2 or vitamin D3). The aim of this study was to measure
the effect of vitamin D supplementation on the change in BMD at
the hip in community-dwelling older people.We also investigated
the effects of supplementation dose on a number of predefined
secondary endpoints including change in plasma 25(OH)D [total
and calculated free 25(OH)D], parathyroid hormone (PTH), and
biochemical markers of bone turnover, as well as the frequency
of falls and adverse events.
Methods
The Vitamin D Supplementation in Older People (VDOP)
Trial (ISRCTN35648481) was a single-center, parallel-group,
participant-randomized, double-blind interventional trial testing
the effects on hip BMD of 3 doses—300, 600, and 1200 μg
(12,000, 24,000, and 48,000 IU)—of oral vitamin D3 given each
month to men and women aged ≥70 y for 1 y as described
earlier (12), with the first dose given between November 2012
and May 2013. The study was funded by Arthritis Research UK
(D19544). Potential participants were identified from electronic
medical records from 25 general practitioner practices in the
northeast of England. Participants were invited to take part
after ensuring they did not meet the following exclusion
criteria:
• treatment with antiresorptive or anabolic treatment for
osteoporosis in the previous 3 y;
• current consumption of supplementary vitamin D at a dose
>10 μg (400 IU)/d or calcium at a dose >500 mg/d;
• experience of a fragility fracture in the previous 6 mo;
• a history of renal stones, previous bilateral hip replacements,
or primary hyperparathyroidism;
• past or present history of hypercalcemia (albumin adjusted
plasma calcium >2.60 mmol/L), hypocalcemia (albumin-
adjusted plasma calcium <2.15 mmol/L), or an estimated
glomerular filtration rate <30 mL · min−1 · 1.73 m−2.
Participants already taking elemental calcium supplements or
vitamin D supplements in equivalent daily doses of ≤500 mg
and 10 μg (400 IU), respectively, were allowed to continue their
supplement. All participants provided written informed consent.
A favorable opinion was obtained from the Tyne and Wear South
Research Ethics Committee (REC, 12/NE/0050), with Research
and Development approval from the sponsor, Newcastle upon
Tyne Hospitals NHS Foundation Trust.
A total of 379 participants were recruited between November
2012 and May 2013. The first participant’s first visit was on 8
November, 2012, and the last participant’s last visit was on 6 June,
2014.
Intervention
Participants were randomly assigned in a ratio of 1:1:1 to 1
of 3 doses of vitamin D3 taken orally each month for 1 y. A
computer-generated allocation list of random permuted blocks
was used to ensure concealment of allocation to subjects and
investigators. Emergency code-break envelopes were retained at
the trials pharmacy, but no code breaking was required during
the study. The medications were identical in appearance so that
neither participant nor investigator was aware of the dose given.
The lowest dose (12,000 IU/mo) corresponded to an approximate
daily dose of 10 μg (400 IU) and was used as a reference
dose, equating to the Reference Nutrient Intake as defined by
the SACN. The second dose (24,000 IU/mo) was equivalent to
the North American Institute of Medicine’s (IOM’s) RDA of
800 IU/d for this age group (3, 13). The highest dose (48,000
IU/mo) is twice the IOM RDA and well below the Tolerable
Upper Intake Level defined by the IOM of 4000 IU/d.
Measurements
BMD at the total hip and neck of femur was measured using
dual-energy X-ray absorptiometry (Lunar iDXA; GEHealthcare)
at baseline and at 12 mo. The scanner was calibrated daily
before participant scanning. Daily phantom measurements were
performed, and precision on repeated measurements was 0.21%,
with no perceptible drift for the duration of the study.
Height and weight were measured, and body composition was
determined by bioelectrical impedance using a Tanita analyzer
(Tanita Corp.) (14). Fracture risk and self-reported falls history
were obtained at baseline, adapted from standard clinical care
questions and the FRAX tool (15).
Participants kept a prospective falls diary with monthly
prompts to record falls made by telephone, at which time they
were also asked about adverse events (AEs), food supplements,
and medication. Participants visited the clinical research facility
every 3 mo, after an overnight fast, when blood and timed urine
samples were collected and further information on AEs and
questionnaires on sunshine exposure, diet, and quality of life
were self-completed. Completed diaries and questionnaires were
discussed with participants at each visit. For details on the study
schedule, please refer to our previous publication (16).
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Biochemical analyses
Blood- and urine-sample collection and processing protocols,
biochemical measurement, methods, and quality control of assay
performance were strictly standardized, as previously described
(12), except for those given below. The 25-hydroxyvitamin D2
[25(OH)D2] and 25-hydroxyvitamin D3 [25(OH)D3] concentra-
tions were determined by liquid chromatography–tandem mass
spectrometry (17). Total 25(OH)D concentration was determined
by summing 25(OH)D2 and 25(OH)D3 concentrations. Assay
performance was monitored using Chromsystems and in-house
controls and is traceable to National Institute of Standards
and Technology standards. The interassay variation was <10%
for 25(OH)D2 and <7% for 25(OH)D3, and the limit of
quantification was 6 nmol/L. External quality assessment was
obtained through participation in Vitamin D External Quality
Assessment Scheme (DEQAS; www.deqas.org).
Vitamin D binding protein (DBP) was measured by polyclonal
antibody ELISA (Immunodiagnostik AG; Oxford Biosystems).
All samples were measured in duplicate, with the exception of
PTH, and the analysis was repeated if the CV was >10%. Assay
performance was measured using kit and in-house controls, and
performance was within acceptable limits. Free concentrations of
25(OH)D were calculated using published mathematical models
(18) that included concentrations of total 25(OH)D, DBP, and
albumin.
Statistical analyses
The primary outcome for the study was the change in
BMD at the hip in response to 12,000, 24,000, or 48,000
IU vitamin D3/mo for 1 y, using 12,000 IU as the reference
dose, with and without adjustment for covariates selected from
the following predetermined potentially confounding variables:
presupplementation plasma 25(OH)D, PTH, weight, height, lean
body mass, estimated glomerular filtration rate, 10-y fracture
risk [FRAX (15)], gender, age, and baseline value of BMD.
During the ANCOVA modeling process, covariates not reaching
a threshold significance of 0.05 were removed, except for age,
gender, weight, and height. The distribution of age was skewed
and was included as a categorical variable based on age at
recruitment grouped by quartile. Other outcomes were analyzed
using this model with consideration of their baseline value rather
than that of BMD.
To compare the absolute change in BMD at the hip, giving
a 2-sided significance level of 0.05 and a power of 80%, 125
participants/arm were required. This resulted in a planned sample
size of 375 participants to allow for 20% attrition by 12 mo. The
estimate was based on the variance in change in BMD over 12
mo from a previous study (19) and enabling detection of a 0.006-
g/cm2 difference (equivalent to a standardized effect size of 0.4)
between 2 arms.
Details of the statistical analysis were predetermined (12)
and constantly reviewed, with revision to evaluate the effects of
circulating free 25(OH)D as well as total 25(OH)D concentra-
tions to address recent development in the scientific field before
unblinding of the data (20). A further post hoc analysis examined
whether participants’ initial circulating 25(OH)D concentration
being above or below 25 nmol/L as a categorical variable
influenced the effect of the supplement and any interaction of this
with trial arm. The statistical analysis plan (SAP 1.4) is available
on request and incorporates a summary of predefined secondary
outcomes, including total femur and femoral neck BMD, serum
total 25(OH)D, plasma PTH, bone turnover markers, falls, and
post hoc analyses outlined in this article, with AE reporting
and the statistical analytical approach adopted. Although no
formal correction for multiple testing has been applied during the
analysis, consideration of Bonferroni correction was made in the
Results and Discussion.
Participant involvement in the study
At the design phase, the research team discussed the intentions
of the study, the research questions and measurements, and
burden to participants with a representative group of older adults
recruited through the Bone Clinic, Freeman Hospital. There were
also 2 lay members on the trial steering group. At the end of the
study, a newsletter was sent to all participants outlining the results
of the study, and the research team answered calls from interested
participants. There was no formal assessment of the burden of
the intervention on health care workload during the study, but we
did collect data on functional outcomes and quality of life (not
included in the primary analysis and yet to be analyzed).
Results
A total of 379 participants were recruited, with 343 (91%)
participants completing the study at 12 mo [see Figure 1; Con-
solidated Standards of Reporting Trials (CONSORT) diagram].
FIGURE 1 CONSORT diagram showing the progression of participants
through the study from invitation by general practitioners to completion.
Treatment allocation and number of participants are given. CONSORT,
Consolidated Standards of Reporting Trials.
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Baseline characteristics, including anthropometric parameters,
markers of calcium and vitamin D metabolism and intakes, renal
function, falls, and major osteoporotic or hip fracture risk, were
well balanced across the 3 arms (see Table 1). There was also
no difference in self-reported habitual sun exposure between the
3 arms at baseline. There were no differences between arms in
subsequent dropout from the study. The mean ± SD baseline
25(OH)D concentration was 40.0 ± 20.1 nmol/L.
There was no significant difference between arms for change
in BMD at the total hip site, comparing 12,000 IU with 24,000
IU (P= 0.39) or with 48,000 IU (P= 0.08). At the femoral neck,
there was no significant difference between 12,000 and 24,000 IU
(P= 0.43) or 48,000 IU (P= 0.62) (see Table 2). However, after
12 mo, there were significant group differences between arms
for change in plasma 25(OH)D (P < 0.01 for comparison of the
lowest dose with either of the 2 higher doses). At 12mo, PTHwas
lower than at baseline for all dosages, with a significant difference
in the decrease in PTH over 12 mo between 12,000 and 48,000
IU (P < 0.01) but not between 12,000 and 24,000 IU (P = 0.78).
For details, see Table 2.
With dose of vitamin D included in the model, there were
no significant associations of baseline PTH, 25(OH)D, fat mass,
height, estimated glomerular filtration rate, or gender with the
change in BMD at the total hip site. However, change in total hip
BMDwas significantly associated with age, which was consistent
with a significant decrease, relative to the youngest quartile,
in the oldest quartile (aged ≥77 y; P = 0.01). Body weight
was significantly associated with an increased positive effect on
change in BMD at this site (P = 0.03) equivalent to ∼0.002
g/cm2 per 10-kg difference in body weight. At the femoral neck,
baseline BMD (P < 0.01), female gender (P = 0.03), and higher
PTH (P = 0.02) were associated with a decrease in BMD.
Further exploratory regression modeling demonstrated that a
higher C-terminal telopeptide (bCTX) at 12 mo was significantly
associated with a decrease in BMD at the total hip (P = 0.01),
whereas a higher baseline PTH was significantly associated with
older age (aged ≥77 y; P = 0.02), weight (P < 0.01), and lower
plasma 25(OH)D (P < 0.01). Post hoc analyses found a dose-
dependent increase in free 25(OH)D, but baseline free 25(OH)D
did not influence BMD in response to the supplement, which
was similar to relations seen for total 25(OH)D and BMD.
Further post hoc analysis found that baseline plasma 25(OH)D>
or <25 nmol/L (as a categorical covariate) did not significantly
show an effect of vitamin D supplementation onBMD, nor was
there any significant interaction of this term with trial arm.
There was no apparent difference in habitual sun exposure
between the doses during the study period. There were no dose
effects of supplement on AEs, including fall frequency (see Table
2). A total of 249 falls occurred among the 141 participants who
fell. The majority of fallers experienced a first fall in the first
3 mo: 27 of 100 total participants (27%) in the 12,000-IU arm,
19 of 95 (20%) in the 24,000-IU arm, and 27 of 97 (28%) in
the 48,000-IU arm. In the second 3 mo, 8%, 13%, and 11% of
participants had a first fall; in the third 3 mo, 7%, 5%, and 5%,
and in the final 3-mo period, 6%, 7%, and 7% of participants,
respectively, fell for the first time. Thus, the proportion who
fell in each arm of the study appeared to be similar for all 3-
mo blocks. There were no symptomatic cases of renal stones or
hypercalcemia, although there were 3 participants who showed
an increased serum-adjusted calcium during the study.
The significant increase in mean plasma 25(OH)D with all
3 doses is presented in Table 3, and, combining the categories
displayed in the table, this demonstrates that 99.7%, 100%,
and 100% achieved a level of ≥25 nmol/L at 12 mo with
12,000, 24,000, and 48,000 IU, respectively. The achievement of
alternative thresholds of 25(OH)D (including 50 and 75 nmol/L)
is also presented in Table 3 and Figure 2. The P values presented
were not adjusted for multiple comparisons. Conclusions around
significant P values are robust to Bonferroni correction for the
change in 25(OH)D, change in free 25(OH)D, and exploratory
association between baseline PTH and baseline 25(OH)D results
above.
Discussion
There was no significant dose effect on BMD at the total femur
or neck of femur when giving a monthly dose of 12,000, 24,000,
or 48,000 IU vitamin D. This is equivalent to a daily dose of
10, 20, or 40 μg (400, 800, and 1600 IU), respectively. The
primary objective of this study was to evaluate the dose effect
of vitamin D supplementation on the attenuation of the age-
associated decline in BMD (12, 19), and our results complement a
recent meta-analysis by Reid et al. (1), which concluded that there
was no clinically significant effect of vitamin D supplementation
on BMD, although that study showed a 0.8% greater BMD at
the neck of femur over a mean study duration of 2 y. A more
recent study (not included in Reid et al.’s meta-analysis) showed a
significant effect of vitaminD supplementation on total hip BMD,
at a dose of 25 μg (1000 IU) but not at 10 μg (400 IU)/d, when
compared with placebo (19). Of note, the latter study, performed
in Aberdeen, United Kingdom, recruited a younger population
than ours (mean age: 65 y), comprising only women who also
had a lower mean serum 25(OH)D concentration at baseline (34
nmol/L) (19). However, it is difficult to compare the results of
either the meta-analysis or the Aberdeen study with the VDOP
because both evaluated the effect of vitamin D compared with
placebo, whereas the VDOP was a dose-ranging study, with the
10-μg (400-IU)/d equivalent dose as reference.
Our population had concentrations of circulating 25(OH)D
comparable to previous UK population surveys, including the
National Diet and Nutrition Survey whose participants aged >65
y had an annualizedmean plasma 25(OH)D concentration of 43.4
nmol/L in men and 47.9 nmol/L in women, with 21% of men
and 9% of women having a plasma 25(OH)D concentration <25
nmol/L. Similar results were also found in the Health Survey for
England in 2005 (21, 16). Participants in our study had dietary
vitamin D intakes slightly higher than, but comparable to, those
seen in the National Diet and Nutrition Survey (2), and overall we
believe that our results are generalizable to the United Kingdom.
Our study found an increase in plasma 25(OH)D and free
25(OH)D with supplementation and a decrease in plasma PTH
with a dose effect on plasma and free 25(OH)D concentrations.
Results for both 25(OH)D and free 25(OH)D were robust to post
hoc Bonferroni correction. The lowest dose, equivalent to 400
IU (10 μg)/d, was sufficient to eliminate vitamin D deficiency in
97% of this population, which is consistent with previous studies
(22). Meta-regression analyses have found a nonlinear relation
between dose of vitamin D and resultant 25(OH)D concentration
(3, 22). Autier et al. (23) found that a daily dose of 1 μg vitamin
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TABLE 3 Plasma 25(OH)D concentrations at baseline and 12 mo by dose1
12-mo category, n (%)
Dose and baseline category Baseline, n (%)
<25
nmol/L
25 to <50
nmol/L
50 to <75
nmol/L ≥75 nmol/L
12,000 IU (n = 112)
<25 nmol/L 31 (27.7) 1 (3.2) 25 (80.6) 5 (16.1) 0 (0.0)
25 to <50 nmol/L 45 (40.2) 0 (0) 13 (28.9) 30 (66.7) 2 (4.4)
50 to <75 nmol/L 30 (26.8) 0 (0) 2 (6.7) 23 (76.7) 5 (16.7)
≥75 nmol/L 6 (5.4) 0 (0) 0 (0) 0 (0) 6 (100)
24,000 IU (n = 113)
<25 nmol/L 30 (26.5) 0 (0) 12 (40.0) 15 (50.0) 3 (10.0)
25 to <50 nmol/L 53 (46.9) 0 (0) 8 (15.1) 34 (64.2) 11(20.8)
50 to <75 nmol/L 23 (20.4) 0 (0) 0 (0.0) 13 (56.5) 10 (43.5)
≥75 nmol/L 7 (6.2) 0 (0) 0 (0.0) 1 (14.3) 6 (85.7)
48,000 IU (n = 113)
<25 nmol/L 33 (29.2) 0 (0) 0 (0) 20 (60.6) 13 (39.4)
25 to <50 nmol/L 53 (46.9) 0 (0) 0 (0) 21 (39.6) 32 (60.4)
50 to <75 nmol/L 21 (18.6) 0 (0) 0 (0) 6 (28.6) 15 (71.4)
≥75 nmol/L 6 (5.3) 0 (0) 0 (0) 0 (0.0) 6 (100)
1Values are n (%) for each category by dose given. For each dose, the last 4 columns present the number (%) ending the study in each category [for
participants with 25(OH)D data at both time points]. IU, international units; 25(OH)D, 25-hydroxyvitamin D.
D3 resulted in an increase in 25(OH)D of 1.95 nmol/L, although
similar doses could result in a 300–400% difference in 25(OH)D
concentrations, presumably related to differing characteristics
between participants, which may be related to factors that include
season (24), gender (25), bodyweight (26), obesity (25), and dose
interval (3), as well as the dose itself, treatment duration, age,
and the 25(OH)D concentration at outset (27). In our study, the
dose-response was also nonlinear, with an increase in 25(OH)D
per microgram of vitamin D3/d of 1.43, 1.27, and 1.00 nmol/L
for 12,000-, 24,000-, and 48,000-IU doses, respectively, which
was less than has been reported elsewhere (3, 22, 23, 27).
Possible explanations for this include altered pharmacokinetics of
vitamin D after daily compared with monthly dosing, leading to
differences in tissue distribution, hydroxylation rate to 25(OH)D,
and catabolism. Also, the fact that there was a month between
dosing and collection of trough blood samples may have resulted
in an apparently lower 25(OH)D concentration compared with
daily dosing.
Our study does not show an effect of dose of vitamin
D on BMD, but it is possible that all 3 doses attenuated
an anticipated decrease in BMD of ∼0.6% over this period
(19) because we had no placebo comparator. An alternative
explanation for studies showing a positive effect of vitamin D
on BMD may be the treatment of a undetected osteomalacia,
which would result in an increase in BMD (9). In the VDOP
study, although baseline 25(OH)D concentration was 6.2 nmol/L
higher than in the study by MacDonald et al. (19), we still
found that 28% had a baseline serum 25(OH)D <25 nmol/L,
which might indicate a risk of osteomalacia and is a similar
proportion to previous UK surveys (21, 16). However, baseline
serum 25(OH)D was not a significant predictor of response to
treatment, and although others have suggested that an increase
in BMD to vitamin D treatment may only be found in those
with a low baseline 25(OH)D (28), in post hoc statistical
analysis we found that baseline serum 25(OH)D <25 nmol/L
was not a significant predictor of response to treatment. However,
our study was not powered for this subgroup analysis and
studies specifically designed to address this hypothesis are
required.
Reporting of AEs was according to International Council for
Harmonization of Technical Requirements for Human Use (ICH)
guidance. Twelve participants withdrew from the study because
of AEs, but only 1 of these withdrawals was related to the
intervention (“feeling unwell related to vitamin D”). There were
low rates of hypercalcemia and urolithiasis, consistent with the
rates expected for this population, with no evidence of a dose
effect (29, 30) and no overall difference in the frequency of AEs
between the vitamin D doses.
It has been suggested that vitamin D supplementation at
doses of 20–25 μg (800–1000 IU)/d decreases the incidence
of falls and fractures in older women, whereas lower doses are
ineffective (31–33). In contrast, other meta-analyses, including
the latest Cochrane Review (34), stress that certain characteristics
of both the population studied and the intervention used influence
efficacy, with studies in older and frail people living in care homes
who were coprescribed calcium with vitamin D supplementation
showing a lower risk of hip and other nonvertebral fracture. In our
study, approximately half of participants reported a fall over 12
mo, which is slightly greater than the estimated 32–42% reported
for this age group (35) but comparable with other vitamin D
studies (36). However, no effect of dose of vitamin D on the
rate of falls was seen. Focusing on studies in older people, a
very high dose of an oral supplement of 12,500 μg (500,000
IU) given annually has been associated with an increased risk
of falls (11), whereas a single intramuscular injection of 7500
μg (300,000 IU) vitamin D2 given to care-home residents had no
effect on hip fracture incidence over 10 mo of follow-up (37).
Another study giving an annual oral dose of 7500 μg (300,000
IU) vitamin D2 for 3 y found an increase in hip fracture risk
(38), although Trivedi et al. (39) found that 100,000 IU vitamin
D3 administered orally every 4 mo was associated with a lower
fracture rate. A recent study found that a monthly oral dose of
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FIGURE 2 Vitamin D status at baseline is presented by category for each monthly dose of supplement: 12,000, 24,000, and 48,000 IU. The colors reflect
the category of vitamin D status at baseline, and the first column shows the number of participants for each category at baseline, with columns 2, 3, 4, and 5
showing the number by category at 12 mo.
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1500 μg (60,000 IU) vitamin D3 was associated with almost 20%
more falls than 600 μg (24,000 IU)/mo (40), whereas another
study in a younger population, using a loading dose of 5000 μg
(200,000 IU) followed by 2500μg (100,000 IU)/mo, did not show
any effect on falls or fracture rate during an average of 3.5 years
of follow-up (41). Finally, a study using a range of daily doses of
vitamin D3, from placebo to 120 μg (4800 IU) in postmenopausal
women showed a significantly lower falls rate in participants
taking 40–80 μg (1600–3200 IU) vitamin D3/d (P = 0.048) than
the highest or lowest doses (36). Thus, the evidence from clinical
trials remains conflicting, and other factors such as the falls rate
before recruitment and baseline 25(OH)D concentration may be
of significance.
We conclude that there was no difference in BMD between
the 3 dosages of vitamin D, which suggests no effect of the
intervention or that all doses may have attenuated the anticipated
decrease in BMD over 12 mo. Monthly dosing with oral vitamin
D3 is a safe and effective strategy to increase plasma 25(OH)D
>25 nmol/L. This is achieved with all 3 doses in the majority
of people and aligns with the current recommendation by the
SACN. The lack of a dose effect on adverse outcomes is
reassuring.
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